Alternative drug to chemotherapy for advanced lung cancer!
Researchers at University of California, LA evaluated an immunotherapy drug, Pembrolizumab.
The drug has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC). The first line treatment means that the drug can be accessed by people without first having to receive treatments viz. chemotherapy.
This drug will allow patients to live longer while delaying, and in some cases potentially avoiding, the side effects of traditional chemotherapy.
No comments:
Post a Comment